Mon, Oct 12
4 itemsToday's digest covers reassuring safety data on first-trimester benzodiazepine use, a large U.S. study linking radon exposure to brain cancer risk, and a possible shared driver of liver and pancreas dysfunction in type 2 diabetes.
First-trimester benzodiazepine use not tied to major birth defects
A population-based cohort study found comparable rates of overall major congenital malformations between pregnancies exposed to benzodiazepines in the first trimester and those that were not, offering reassurance about these medications.
Why it mattersMay ease prescribing decisions and anxiety for pregnant patients and clinicians managing conditions such as anxiety, insomnia or epilepsy.
Radon exposure linked to higher brain cancer risk in large U.S. cohort
Long-term tracking of nearly 160,000 people across the United States suggests brain cancer risk rises as radon exposure increases.
Why it mattersCould strengthen arguments for home radon testing and mitigation as a cancer-prevention measure.
Shared signaling regulator may link liver and pancreas dysfunction in type 2 diabetes
Researchers describe a shared signaling regulator that may connect excess liver glucose production with insufficient insulin secretion from pancreatic beta cells in type 2 diabetes.
Why it mattersIdentifying a common pathway could point toward therapies targeting both organs rather than treating each defect separately.
GLP-1 weight loss drugs linked to nail detachment and hair loss
Researchers report unexpectedly high rates of nail detachment, hair loss and scalp inflammation among users of GLP-1 drugs such as Ozempic and Wegovy, with some problems several times more frequent; weight loss alone did not fully explain the differences.
Why it mattersAdds to the safety profile patients and prescribers should weigh when starting or continuing these widely used drugs.